Clinical trial
Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009…
NCT00175019 · Takeda, Industry · Completed
Key facts
| NCT number | NCT00175019 |
|---|---|
| Title | Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 |
| Official title | A Phase 3, Open-Label, Randomized, Allopurinol-Controlled Study to Assess the Long-Term Safety of Oral Febuxostat in Subjects With Gout |
| Acronym | EXCEL |
| Lead sponsor | Takeda, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gout |
| Intervention type | Drug |
| Interventions | Febuxostat, Allopurinol |
| Enrollment | 1,086 |
| Start date | Jul 1, 2003 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Sep 15, 2005 |
| Last update posted | Jul 27, 2010 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: